BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
KyeongJin Kim1,2 (Professor), Wen-Hao Yang3 (Professor), Youn-Sang Jung4 (Professor), Jong-ho Cha1,2,* (Professor)
1Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 22212,,
2Department of Biomedical Science and Engineering, Graduate school, Inha University, Incheon 22212, Republic of Korea,
3Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan,
4Department of Life Science, Chung‐Ang University, Seoul 06974, Republic of Korea
T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-T-cells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend’s potential as an adjuvant for cancer immunotherapy.
Abstract, Accepted Manuscript [Submitted on July 14, 2020, Accepted on July 31, 2020]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd